MIV posts positive one-year data on polymer-free DES, with no Plavix for 8 months
MIV Therapeutics, a developer of next-generation coatings and drug-delivery systems for cardiovascular stents, has reported positive safety and efficacy results at 12-month clinical follow up for all 15 patients in its first-in-man (FIM) VESTASYNC I trial of its VESTAsync polymer-free drug-eluting stent.

In addition, data using intravascular ultrasound (IVUS) and quantitative coronary angiography (QCA) have now been generated for all 15 patients at nine-month follow-up, which showed no difference from the safety and efficacy data on 11 and 12 patient nine-month data presented at the American College of Cardiology (ACC) conference in March.

“We are very excited that the data from the VESTASYNC I FIM Trial continue to show excellent safety and efficacy, with no major adverse cardiac events for all 15 patients involved. Significantly, at this point all of our patients are Plavix-free, and have been so for at least eight months, which suggests that the VESTAsync drug-eluting stent has the potential to reduce the current treatment paradigm for these patients to short-term anti-coagulant therapy from the current standard of a minimum of one year,” said Mark Landy, MD, MIV president and CEO.